908 Devices Third Quarter 2026 Financial Results Conference Call - 908 DEVICES INC

Financial Performance:

• Q3 2026 revenue reached $19 million, a 35% year-over-year increase, driven by FTIR products (55% of mix) and NearLab law enforcement revenue.
• Total device shipments exceeded 300 units, bringing the global installed base to approximately 4,400 units.
• Recurring revenue grew to $5.1 million (27% of total revenue), primarily fueled by software subscriptions and higher FTIR service revenue.
• Gross margin was 53%, while adjusted gross margin was 58% (down 40 bps YoY) due to lower-margin international product mix.
• Adjusted EBITDA loss narrowed to $1.7 million from $1.8 million in the prior year, with the company targeting mid-single-digit millions in loss for the full year.
• Net loss improved to $4.6 million from $14.9 million in the prior year, aided by an $11 million non-cash reduction in contingent consideration fair value changes.
• Cash position stood at $99.1 million with no outstanding debt; Q3 net cash consumption was $2.4 million.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $68.5–$70 million, implying 22–25% growth over 2025.
• Q4 revenue growth is projected at 20% at the midpoint; achieving the high-end guidance ($70M) requires ~24% Q4 growth, contingent on closing key Viper and mass spec opportunities.
• Full-year 2026 adjusted gross margin expected in the mid-to-high 50% range.
• 2027 growth drivers identified as NearLab expansion, Next-Gen MX908 shipments (early access late 2026), and potential AFCAD/COTS program wins.
• Long-term goal for recurring revenue remains in the 30–40% range of total revenue.

Business Segments and Product Lines:

• FTIR/Protector: Shipped >200 units, including two-thirds of a $6M Asia-Pacific corrections order; secured two government wins in Europe (EOD teams) including a >$2M framework agreement.
• Mass Spec (MX-908): Maintained category leadership against evolving synthetic opioid threats (e.g., cyclorphine); delivered devices to U.S. military for immediate capability gaps.
• NearLab: Sold ~100 devices in Q3 (up from 35 in the prior two months post-acquisition); surpassed 1 million cumulative scans; 50% of placements were to new customers (U.S. state/local and international).
• Viper & Explorer: Major U.S. transportation agency placed first Viper order, exemplifying the "land and expand" strategy across the portfolio.
• Next-Gen MX-908: Pilot manufacturing underway; targeted for early access shipping late 2026; features reduced size, enhanced selectivity, and integrated Team Leader software.

Market and Competitive Landscape:

• International revenue accounted for 40% of Q3 total, double the prior year, driven by global defense budget increases and channel partnerships.
• The company is competing in the EOD modernization cycle and aerosol detection market against A-series nerve agents and pharmaceutical-based aerosols.
• U.S. government testing for the AFCAD program is underway with a view toward a Commercial Off-The-Shelf (COTS) decision in 2027; 908 Devices positions its MX-908 as a preferred COTS alternative to in-house development.
• Customer concentration risk noted in Q3, with ~41% of revenue from two customers (primarily channel partners for the Asia-Pacific Protector order).
• Competitive moat strengthened by "Team Leader" fleet management software and expert "Reachback" support services.

Risks and Challenges:

• Revenue volatility due to dependency on large, infrequent government procurement cycles and funding timing (e.g., DHS grant flows).
• Potential revenue drag from the lapse of a specific mass spectrometry service contract in Q4 2026.
• Margin pressure from a temporary shift in product mix toward lower-margin international shipments.
• Execution risk in scaling supply chain and manufacturing capacity for the Next-Gen MX-908 to meet potential 2027 demand.
• Evolving chemical threat landscape (synthetic opioids like cyclorphine) requires continuous R&D investment to maintain detection library relevance.

Management Commentary and Tone:

• Management tone was confident and optimistic, describing Q3 as "strong across the board" with "record" device shipments.
• Emphasized operational discipline, highlighting the structural cost base reset from 2025 that allows for strategic investment without overspending.
• Expressed pride in the successful integration of NearLab, noting immediate commercial synergies and accelerated adoption.
• Confident in the "connected services" model, arguing that hardware becomes more valuable over time as software libraries update for new threats.

Analyst Questions and Answers:

• Order Dynamics (Learink): Management clarified no major order pull-forward in Q3; Q4 growth depends on securing funding for key Viper/mass spec deals, with a single large channel order (Asia-Pacific) skewing Q3 concentration.
• NearLab Pipeline (Roth): Pipeline described as robust; 100+ Q3 placements included many new customers; targeting ~3M scans in Q4 and 5M+ in 2027.
• AFCAD COTS Economics (Roth): If AFCAD adopts a COTS path, 908 could realize mid-50s commercial margins vs. 30–40% OEM margins, potentially triggering revenue in 2027.
• Recurring Revenue (Cowen): Focusing R&D on software monetization (Team Leader, cloud subscriptions); aiming to expand recurring revenue share to the high 30s/40s via bundled support and data analytics.
• State & Local Funding (Canaccord): Q3 dip in state/local was timing-related following strong Q1/Q2 wins; multi-year grant programs (UASI, AFG, COPS) remain funded and active, providing stability for Q4 and 2027.
• Supply Chain (William Blair): Manufacturing for Next-Gen MX-908 is active in Danbury, CT; beta feedback is positive, with international partners requesting demo units.
• Service Revenue (Stiefel): Mass spec service decline attributed to a specific lapsed contract; FTIR service continues to grow; management expects recurring revenue to resume growth excluding NearLab as that contract lapses.

Other Key Points:

• The MX-908 is uniquely positioned to detect "orphan" synthetic opioids (e.g., cyclorphine) via mass spectrometry, offering programmable updates that fixed-detection methods cannot match.
• The "Team Leader" platform currently interfaces with FTIR but will expand to the Next-Gen MX-908 and NearLab to enable enterprise-level fleet management and data trend analysis.
• New regulatory tightening on synthetic kratom and cannabis in the U.S. is driving demand for NearLab's rapid, cloud-updatable identification capabilities.
• The company views its portfolio as non-competitive internally; adding new platforms (Viper, NearLab) expands customer detection coverage rather than cannibalizing existing revenue.